|
|
||||||||


* Wisconsin Regional Primate Research Center and
Department of Obstetrics and Gynecology, University of Wisconsin, Madison, WI 53715; and
Fred Hutchinson Cancer Research Center, Seattle, WA 98104
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
2-microglobulin and interacts with a
variety of receptors on cells of the innate immune system, including NK
cells and monocytes (7, 8, 9, 10, 11). One of the intriguing
characteristics of the molecular biology of HLA-G is the expression of
an alternatively spliced transcript coding for a truncated, soluble
molecule (12, 13), now designated HLA-G5. These studies
have also identified intron 4-retaining isoforms lacking the
2
domain (HLA-G6). In these transcripts, the fourth intron is retained,
and the reading frame of the intron results in a unique 21-aa carboxyl
terminus following the fourth exon. A stop codon in the intron 4
sequence deletes the 41 aa of the fifth and sixth exons, including the
transmembrane domain. Initial studies with an Ab (16G1) raised against
the unique C-terminal extension detected the protein within the
placenta (14), but not in peripheral lymphocytes. In
addition, several groups have now reported assays for detecting soluble
HLA-G in peripheral blood and other biological fluids
(15, 16, 17, 18). Unexpectedly, soluble HLA-G was detected not
only in pregnancy, but also in nonpregnant women as well as males.
Recent studies suggested that HLA-G5, one isoform of soluble HLA-G, can
induce apoptosis in peripheral CD8+ T cells via a
Fas-Fas ligand mechanism (19), can suppress an allogeneic
proliferative T cell response in mixed lymphocyte cultures
(20), and can inhibit peripheral blood NK cell-mediated
cytotoxicity (21). These results collectively suggest that
while membrane-bound HLA-G may interact with resident leukocytes within
the decidua, soluble HLA-G may act on blood cells in the peripheral
circulation in both pregnant and nonpregnant individuals. The consistent observation of soluble HLA-G in nonpregnant women as well as men raises a number of provocative questions, including the source(s) of this molecule as well as its function both during and outside the setting of pregnancy. To address these questions in an experimental animal model, we have characterized the expression of a nonclasical MHC class I molecule, Mamu-AG, a putative HLA-G homolog, in the rhesus monkey placenta. Mamu-AG shares a number of biochemical and molecular features of HLA-G, including a relatively low level of polymorphism, the presence of alternatively spliced mRNAs and multiple isoelectric isoforms, and a high level of expression at the maternal-fetal interface (22, 23, 24). We have also previously shown that, as with HLA-G, the mRNA for Mamu-AG has restricted expression in extraplacental tissues (25). In the current study we have shown that the placenta as well as the testis in the rhesus monkey expresses a transcript that could encode a soluble Mamu-AG retaining the fourth intron, which contains a premature stop codon. Both placenta and testis demonstrate reproducible immunostaining with mAb 16G1, raised against the fourth intron-encoded C-terminal peptide of HLA-G. Expression in the testis was strikingly cell specific, suggesting that the rhesus monkey will be an excellent model to study the physiology of a soluble nonclasical MHC class I molecule.
| Materials and Methods |
|---|
|
|
|---|
Adult female rhesus monkeys (Macaca mulatta) used for timed matings were from the colony maintained at Wisconsin Regional Primate Research Center. Rhesus monkey placental tissues were obtained by cesarean section as we have previously described (26). Other tissues were obtained from healthy animals euthanized in other studies. All surgical procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and under approval of the University of Wisconsin Graduate School animal care and use committee.
RT-PCR, cloning, and sequencing
In RT-PCR experiments, 1 µg total RNA was reverse transcribed
to cDNA using an oligo(dT) primer and Moloney murine leukemia
virus reverse transcriptase (PerkinElmer, Foster City, CA). The
cDNA was amplified for 34 cycles, with each cycle consisting of 94°C
for 30 s, 55°C for 30 s, and 72°C at 1 min, in a reaction
mixture containing 10 mM Tris-HCl, 1.5 mM MgCl2,
50 mM KCl, 0.25 mM of each dNTP, and 1.25 U AmpliTaq DNA polymerase
(PerkinElmer). Primers used for the amplification and sequencing of
rhesus MHC class I cDNAs are depicted in Table I
. Amplification reactions using as
template RT reactions to which no RNA or no reverse transcriptase had
been added served as negative controls. The PCR products were separated
on 3% agarose gels, isolated with the GeneClean II kit (BIO 101,
Vista, CA), and subcloned using a TA cloning kit (Invitrogen, Carlsbad,
CA). Subcloned fragments were sequenced using an ABI 377 automated
sequencing machine and the BigDye Terminator mix (PE Applied
Biosystems, Foster City, CA).
|
Tissues collected at surgery or necropsy were immediately
prepared for frozen sections. After fixing in 2% paraformaldehyde for
4 h, the tissues were washed with PBS twice for 20 min each time.
They were then dehydrated in 9% sucrose for 4 h and 20% sucrose
overnight. The tissues were then embedded in OCT mounting medium
(Sakura Finetek U.S.A., Torrance, CA) and frozen in isopentane cooled
with dry ice and ethanol. The mouse mAbs 25D3, 16G1, and goat
anti-
2-microglobulin (DAKO, Carpinteria,
CA) were used at a concentration of 5 µg/ml. W6/32 was used at 1
µg/ml. A mouse IgG1
Ab (Sigma-Aldrich, St. Louis, MO) or goat
polyclonal IgG antiserum (Santa Cruz Biotechnology, Santa Cruz, CA)
were used as negative controls at the same concentrations as the
primary Abs. Immunostaining was performed as previously reported
(23, 24). Peptide blocking experiments were performed on
placental and testicular sections with 16G1 by incubating the Ab with
its immunizing peptide or a nonspecific peptide, GnRH, as a control.
The Ab was mixed with either peptide at molar concentrations of 4/1 and
10/1 (peptide/Ab) and incubated for 30 min at 0°C. During this time,
the sections were blocked with animal serum. After Ab neutralization,
the mix was added to the sections for 1 h. 16G1 alone and mouse
IgG were used as additional controls. The remainder of the procedure
was performed as described above. Peroxidase and alkaline phosphatase
kits were used along with diaminobenzidene, Vector NovaRed, Vector Red,
and Vector Blue substrate kits (Vector Laboratories, Burlingame, CA).
Some slides were counterstained with hematoxylin.
In situ hybridization (ISH)4
For ISH, placental and testicular tissues were prepared for paraffin sections. Tissues were fixed in 2% paraformaldehyde for 4 h and then embedded in paraffin. Ten-micrometer sections were cut and processed as previously described (23). A digoxigenin-labeled 141-bp RNA probe derived from exon 2 of Mamu-AG, as described previously (23), was generated for ISH (digoxigenin labeling kit, Roche, Indianapolis, IN). Transcription of sense and antisense RNA was confirmed by dot blot and gel electrophoresis. Hybridization buffer containing 400 µg/ml probe was applied to sections, which were then covered with a glass coverslip to prevent drying, and incubated at 55°C for up to 40 h. Slides were washed extensively to ensure specific hybridization (23). The slides were washed in 2x SSC with 0.1% SDS (0.3 M sodium chloride and 0.03 M sodium citrate) for 30 min, placed in 2x SSC at 60°C for 1 h, 0.2x SSC at room temperature for 15 min, and 0.1x SSC at 60°C for 1 h. Sections were blocked with 25% goat serum in PBS for 30 min and then incubated with alkaline phosphatase conjugated anti-digoxigenin (1/2000; Roche) for 2 h. Sections were washed in TBS for 2, 10, and 10 min. Slides were incubated in detection buffer for 5 min and then covered with the substrate BM-purple (Roche) overnight.
Recombinant Mamu-AG5 expression and Western blotting
The RNA for Mamu-AG5 was amplified using RT-PCR and primers in
exons 2 and 6 containing the start codon and the stop codon,
respectively (Table I
, primers 6 and 7). The sequence for an
enterokinase cleavage site (GACGATGACGATAAG) and hemagglutinin (HA)
protein tag (TACCCATACGATGTTCCGGATTACGCTAGCCTC) were then added to
the 3' region of the transcript by a second round of PCR. The resulting
cDNA was directly sequenced and subcloned into pGEM vector (Promega,
Madison, WI) for subsequent transfection into 293 cells. 293 cells were
transiently transfected according to a standard calcium phosphate
transfection procedure, and cells were harvested after 48 h of
culture, lysed, and prepared for Western blotting. Protein samples were
prepared from cultured transfected 293 cells by lysis in 25 mM
Tris-phosphate (pH 7.8), 2 mM DTT, 2 mM
1,2-diaminocyclohexane-N,N,N',N'-tetraacetic
acid, 10% glycerol, and 1% Triton X-100 , (E1531; Promega). Samples
were quantitated using the Bradford assay. Discontinuous SDS-PAGE was
performed using a 10% acrylamide resolving gel and a 3.9% stacking
gel. Fifty to 100 µg cell extract was fractionated along with Rainbow
markers (RPN 800; Amersham, Arlington Heights, IL) to estimate m.w.
After electrophoresis, proteins were electroblotted onto a
polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA). The
membrane was washed twice with TBS and blocked with a 0.2% nonfat dry
milk/TBS solution overnight at 4°C. Following blocking, the membrane
was washed three times with a 0.1% Tween 20/TBS solution, then
incubated with the anti-HA Ab (0.5 µg/ml; Roche) or 16G1 (5
µg/ml) for 2 h at room temperature. The membranes were washed
three times for 10 min each time and then incubated with alkaline
phosphatase-conjugated goat anti-mouse secondary Ab (1/3000;
Bio-Rad) for 1.5 h. The membrane was washed three times and
incubated with Immun-Star chemiluminescent substrate solution (Bio-Rad)
for 5 min, and immunoreactive bands were visualized by
autoradiography.
| Results |
|---|
|
|
|---|
We investigated whether the placenta expresses a transcript for
Mamu-AG retaining intron 4, as with the
soluble HLA-G transcripts previously reported in the human
placenta and other tissues. First, we amplified reversed transcribed
cDNA with primers 2 and 5 located in the fourth and sixth exons,
respectively, reasoning that since the mRNA was only detectable by
RT-PCR in human placenta, we might find the same situation with the
rhesus placenta. Fig. 1
B
demonstrates that several amplicons dependent on reverse transcription
were obtained from rhesus placental RNA. Whereas the major band seen in
Fig. 1
B primarily contained the expected sequences of the
fourth, fifth, and sixth exons, cloning and sequencing of the band
indicated by an arrow revealed the presence of an intron highly
homologous to the human HLA-G intron (see below). The intron
sequence from this mRNA was confirmed to represent intron 4 in its
entirety by sequencing PCR product amplified from rhesus genomic DNA
(not shown). Most significantly, a stop codon was noted at the same
location as that for soluble HLA-G (Fig. 1
C).
Since the intron 4-containing PCR amplicon might be derived from a
splicing intermediate, we sought to confirm the splicing at exon-intron
junctions 5' from the fourth intron region in putative soluble
Mamu-AG transcripts. For this experiment we designed
downstream primer 4 within the fourth intron, and upstream primer 1
within the second exon (
1 domain) to determine whether transcripts
containing the fourth intron also contained other upstream introns. We
cloned and sequenced seven placental cDNAs amplified by these primers
from three different placentas, and none was found to contain intron 2
or 3 (not shown). We concluded that the soluble Mamu-AG
cDNAs represent mature mRNAs retaining only the fourth intron. In
addition, these clones all contained exons 2, 3, and 4, demonstrating
that in our hands only a Mamu-AG mRNA homologous to
HLA-G5 is detected in the placenta.
|
Soluble Mamu-AG mRNA in rhesus nonplacental tissues
Our previous studies of the expression of Mamu-AG demonstrated
that the mRNA is expressed in a variety of tissues, with the highest
nonplacental level of Mamu-AG mRNA in the testes
(25). Those studies were conducted with a ribonuclease
protection assay selective for the Mamu-AG
1 domain
(exon 2). We re-evaluated a number of rhesus nonplacental tissues by
RT-PCR with primers 3 and 5 that would selectively amplify mRNAs
containing the exon 4/intron 4 junction. Fig. 1
G presents
representative results from several tissues. As expected, placental
tissues had abundant intron 4-containing Mamu-AG mRNA, while
in most tissues this isoform was undetectable (eye, adrenal, lymph
nodes, skeletal muscle, skin, heart, lung, liver, and pancreas; not
shown) or barely detectable (ovary, Fig. 1
G; kidney and
intestine, not shown). Several tissues had a moderate, but consistent,
expression of intron 4-containing mRNA, including amniotic membranes,
testes, spleen (Fig. 1
G) and thyroid (data not shown).
Although to our knowledge the retention of intron 4 is unique in humans
to HLA-G and is not known in classical loci, the question arose of
whether the PCR fragments amplified represented rhesus classical loci.
Sequencing of multiple PCR-generated clones from both testicular and
placental RNA indicated that all transcripts from these tissues
contained an entire intron 4, and all contained the diagnostic TAA stop
codon in exon 6. Four of the six testicular and one of three spleen
(but none of 19 placental) clones sequenced that retained intron 4 also
contained 18 nt of the 3' end of intron 5 discussed above. Since the
stop codon was located within intron 4, the intron 5 sequences do not
contribute to the coding sequence for these nonplacental transcripts.
Several amplicons from thyroid and spleen also were found to contain
the stop codon diagnostic for Mamu-AG (Fig. 2
) (22, 27, 28).
Surprisingly, one transcript from spleen and two from thyroid were
apparently derived from classical MHC class I molecule(s), since they
did not contain the diagnostic stop codon (Fig. 2
). Further work will
be required to understand the significance of this observation.
|
We wished to explore the expression of soluble Mamu-AG isoforms in
rhesus monkey tissues with the Ab 16G1 raised against the
carboxyl-terminal region of soluble HLA-G encoded by intron 4
sequences. To evaluate recognition of Mamu-AG5 by 16G1, a Mamu-AG5 cDNA
was cloned into an expression vector containing sequences encoding an
in-frame HA tag at the 3' end of the Mamu-AG5 cDNA. 293 cells were
transiently transfected with the construct, and cell extracts of
transfected and naive cells were analyzed by Western blot. Parallel
analysis was performed with 16G1 and an Ab against the HA epitope (Fig. 3
). Fig. 3
A demonstrates that
extracts of transfected, but not naïve, cells expressed three
immunoreactive bands of
3539 kDa as identified by the anti-HA
Ab. Fig. 3
B demonstrates that an identical trio of bands was
identified by Ab 16G1 in transfected, but not naïve, cells.
|
We next conducted immunocytochemical analysis for Mamu-AG in these
tissues, evaluating three placentas and testes and epididymi from five
different animals. We used an mAb (25D3) against Mamu-AG we have
previously described (24), as well as an mAb against the
intron 4 peptide of HLA-G (16G1) (12). Consistent
with previous reports, 25D3 identified Mamu-AG on the villous syncytial
apical membranes (Fig. 4
, A and
H), in the proximal columns (Fig. 4
F), and in the
cytotrophoblastic shell delineating the maternal-fetal interface (Fig. 4
J). Mesenchymal cells in the core of the villi (Fig. 4
H) as well as the maternal decidua and uterus were
consistently negative.
|
We next conducted similar immunostaining experiments with rhesus
testes. 25D3 staining in the testis was minimal and was localized
exclusively to occasional cells in the interstitium surrounding the
seminiferous tubules (Fig. 5
G). Germ cells and Sertoli
cells within the tubule were consistently negative. Although only
occasional interstitial cells were 25D3 positive, these cells were
found to be consistently positive on serial sections, occasionally
appearing in small aggregates. Other sporadic cells were typically
within peritubular regions, and immunostaining of serial sections
suggested that at least some of these cells were positive for CD68,
indicating their likely identity as macrophages (Fig. 5
H).
Serial sections (Fig. 5
, FH) demonstrate interstitial
macrophages that appear to coexpress Mamu-AG, soluble Mamu-AG, and
CD68. Epidydimal structures and mature sperm were not positive for
Mamu-AG with 25D3 (not shown).
|
|
|
2-microglobulin, it seemed possible that 16G1
immunostaining is detecting soluble Mamu-AG H chain that is not
complexed with
2-microglobulin. Immunostaining
confirmed this hypothesis (Fig. 5
2-microglobulin was
identified within the interstitial tissue, the seminiferous tubules
were devoid of immunostaining. Interestingly, Sertoli cells do not
express
2-microglobulin. We also evaluated several tissues previously shown to express low levels of Mamu-AG mRNA (25). Adrenal, spleen, ovary, kidney, heart, and pituitary samples did not reveal any Mamu-AG expression by immunostaining with 25D3 or 16G1 (data not shown).
Mamu-AG ISH
Immunocytochemical analyses indicated that the Mamu-AG
transcripts we detected by RT-PCR were expressed in the seminiferous
tubules. To confirm that the tubules contain Mamu-AG mRNA,
we conducted ISH with a probe for the
1 domain, with which we have
previously defined conditions for locus-specific ISH (23).
As we have previously reported, the villous syncytiotrophoblasts and
trophoblastic shell consistently expressed Mamu-AG mRNA
(Fig. 7
A). In addition,
villous cytotrophoblasts and occasional cells within the core of the
villi were positive (Fig. 7
B). Maternal decidua and uterine
tissue were always negative, and no hybridization was observed with the
sense probe (Fig. 7
C).
|
Finally, we conducted RT-PCR for Mamu-AG mRNA exons 46 with samples of ejaculated rhesus sperm. Cloning and sequencing of amplified cDNAs revealed that both whole semen and "swim-up" fraction sperm contained Mamu-AG mRNA; however no transcripts containing intron 4 were detected.
| Discussion |
|---|
|
|
|---|
Soluble MHC class I molecules can be generated by several mechanisms. Molecules can be shed from the cell surface, or surface-bound molecules may be liberated by extracellular proteases (29). In addition, alternative splicing can generate MHC class I isoforms that are released from the cell. Classical MHC transcripts lacking exon 5, which encodes the transmembrane domain and therefore will be released from expressing cells, have been identified in the human and the mouse (30, 31, 32). Although the role(s) of soluble MHC is not completely defined, it may be involved in immunoregulation and tolerance in the setting of organ transplantation (33).
A novel mechanism for generating a soluble MHC class I molecule was
revealed in studies of HLA-G, a nonclassical molecule expressed at high
levels in the human placenta. Exon 5 encodes the membrane-spanning
domain, and exons 68 encode the short cytoplasmic domain, which
contains a stop codon 18 aa upstream of the conventional MHC class I
molecule stop codon. An HLA-G transcript that included the
fourth intron was first identified in placental RNA (12, 13). Translation of the intron results in an in-frame stop codon
that terminates the protein upstream of the transmembrane domain. The
resulting protein has a novel carboxyl terminus and is able to complex
with
2-microglobulin, but would be released
from the cell due to the lack of a transmembrane domain (12, 13). In addition to the placenta (14, 34), soluble
HLA-G has also been reported in CD4+ T cells
(20), activated monocytes (35), thymic
epithelium (36), and lung tumor cells (37).
It is intriguing that like HLA-G, the Mamu-AG
gene also is alternatively spliced to give rise to a soluble molecule.
The retention of this novel splicing pattern is an additional facet of
the molecular biology of the Mamu-AG locus that suggests a
close functional homology with HLA-G. The splice patterns of
HLA-G are complex, with various combinations of exons
identified in human normal and transformed cells (12, 13, 38, 39, 40). However, the mechanisms that control splicing patterns
in different cell types are not understood. Whether the mechanisms that
direct the retention of intron 4 in Mamu-AG are related to those
controlling HLA-G gene expression remains to be determined. A
difference noted between the soluble HLA-G and soluble Mamu-AG isoforms
is that whereas the predominant soluble HLA-G isoform may be HLA-G6
(18), we did not detect Mamu-AG6 mRNA in the
rhesus placenta, although the rhesus clearly expresses membrane-bound
Mamu-AG2 mRNA (22, 25). Alternatively, perhaps
the placenta is not the primary source of circulating HLA-G.
An mAb (16G1) directed at the soluble HLA-G carboxyl-terminus tail
(12) has been used to study the expression of soluble
HLA-G isoforms in the human placenta. Using this Ab, soluble HLA-G has
been localized within the extravillous trophoblasts and has been
reported in association with human villous cytotrophoblasts as well as
in some cases with the syncytiotrophoblasts (5, 14) and
villous endothelial cells (34). Finally, some macrophages
within the placental villi were also seen to express soluble HLA-G
(14). It is intriguing that our current results generally
parallel these observations in the human placenta. Soluble Mamu-AG is
also noted not only in syncytiotrophoblasts, but within cells of the
villous stroma, apparently including Hofbauer cells, and villous
cytotrophoblasts of the rhesus placenta. Our previous studies have
shown that
2-microglobulin is readily detected
within rhesus syncytiotrophoblasts and in villous stromal cells, but
very low staining is found within villous cytotrophoblasts
(23). The immunostaining pattern obtained with 16G1 would
suggest that villous cytotrophoblasts, but not syncytiotrophoblasts or
Hofbauer cells, are likely to produce free H chain Mamu-AG. Recently,
several groups have sought to establish whether soluble HLA-G is
present in the serum of pregnant women (15, 16, 17, 18).
ELISA-based assays using various Ab capture and detection approaches
have indicated the presence of soluble HLA-G not only in the serum of
pregnant women, but also in nonpregnant women and in men as well.
Whether soluble Mamu-AG is detectable in the serum of the rhesus monkey
remains to be investigated.
The pattern of expression of soluble Mamu-AG expression in the placenta overlaps but is not identical with that of the membrane-bound molecule. This may reflect the putative targets for these two isoforms. Soluble Mamu-AG immunoactivity was relatively low in rhesus extravillous cytotrophoblasts, whereas membrane-bound Mamu-AG was readily detected. One might speculate that membrane-bound HLA-G and Mamu-AG on extravillous trophoblasts will ligate receptors on adjacent decidual leukocytes to regulate their activity, whereas a soluble circulating molecule may modulate maternal immune cell activity both locally, within the decidua, as well as systemically. In this situation the syncytiotrophoblasts are a more effective way to release a soluble molecule directly into the maternal circulation. The expression of soluble HLA-G by the syncytiotrophoblasts remains somewhat controversial (5, 14, 41), and detection may be dependent on the conditions used for fixation, embedding and processing as well as the Abs used. Indeed, conflicting results on placental and extraplacental localization of HLA-G support both further study as well as the development of appropriate animal models.
The pattern of soluble MHC class I expression in the rhesus testis was
unexpected. HLA-G protein was not detected in human testes in previous
studies (5, 41), although mRNA expression has been
reported in some, but not all, studies (42, 43). In our
studies with the rhesus, whereas there was only very rarely detectable
membrane-bound Mamu-AG within the seminiferous tubules (as determined
by 25D3 staining), it was clear that abundant soluble protein was
present in selected germ cell populations, colocalized with Mamu-AG
mRNA. The lack of
2-microglobulin within the
rhesus seminiferous tubules sufficiently explains the lack of cell
surface protein, an observation made previously with the human testis
and the pan-MHC class I Ab W6/32 (43). Free class I H
chain was detected in some spermatocyte populations in humans
(43). However, it seems unlikely that testicular
soluble HLA-G may be the source of circulating serum HLA-G in men,
since the patency of the blood-testis barrier would preclude this route
of trafficking of the molecule. In addition, the assays used to detect
soluble HLA-G typically detect the class
I-
2-microglobulin complex
(15, 16, 17, 18), and immunostaining of human testes with 16G1 did
not detect soluble HLA-G protein (41). Thus, another site
of expression of human soluble HLA-G seems likely.
It is intriguing to speculate on a function for seminal soluble Mamu-AG in the female reproductive tract, perhaps suppressing an innate immune response within the vagina or the uterus to male leukocytes within the ejaculate. A role in controlling T cell expansion, blocking CTL activity, and inducing apoptosis in alloreactive T cells has been suggested for soluble HLA-G (19, 20, 44). Alternatively, soluble Mamu-AG might also help prevent anti-sperm immune responses following minor breaks in the blood-testis barrier of the seminiferous basement membrane. In one tubule we noted high expression of membrane-bound Mamu-AG on a cellular aggregate (not shown) that also stained positively for the macrophage marker CD68. The expression of HLA-G has been noted in macrophages invading psoriatic skin lesions (45) and in activated macrophages and dendritic cells in lung tumors (34, 46). Although the expression of soluble or membrane-bound HLA-G in placental macrophages is not fully resolved (5, 14, 41), the rhesus monkey may be an experimental model in which to explore the functional significance of soluble nonclassical MHC class I molecules in vivo.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 A.F.R. and R.L.G. contributed equally to this work. ![]()
3 Address correspondence and reprint requests to Dr. Thaddeus G. Golos, Wisconsin Regional Primate Research Center, University of Wisconsin, 1223 Capitol Court, Madison, WI 53715-1299. E-mail address: golos{at}primate.wisc.edu ![]()
4 Abbreviations used in this paper: ISH, in situ hybridization; HA, hemagglutinin. ![]()
Received for publication October 26, 2001. Accepted for publication May 10, 2002.
| References |
|---|
|
|
|---|
-activated macrophages but not placental fibroblasts. Hum. Immunol. 59:435.[Medline]
and chorionic somatomammotropin messenger ribonucleic acid expression by 8-bromo-adenosine 3',5'-monophosphate and dexamethasone in cultured rhesus monkey syncytiotrophoblasts. Endocrinology 131:89.
2m-free class I heavy chains are intermediates in generation of soluble HLA by the membrane-bound metalloproteinase. Hum. Immunol. 60:1216.[Medline]
This article has been cited by other articles:
![]() |
G. I. Bondarenko, D. W. Burleigh, M. Durning, E. E. Breburda, R. L. Grendell, and T. G. Golos Passive Immunization against the MHC Class I Molecule Mamu-AG Disrupts Rhesus Placental Development and Endometrial Responses J. Immunol., December 15, 2007; 179(12): 8042 - 8050. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. V. F. Hviid HLA-G in human reproduction: aspects of genetics, function and pregnancy complications Hum. Reprod. Update, May 1, 2006; 12(3): 209 - 232. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Hannan, R. L. Jones, C. A. White, and L. A. Salamonsen The Chemokines, CX3CL1, CCL14, and CCL4, Promote Human Trophoblast Migration at the Feto-Maternal Interface Biol Reprod, May 1, 2006; 74(5): 896 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Le Bouteiller Human villous trophoblast and the lack of intron 4-retaining soluble HLA-G secretion: beware of possible methodological biases Mol. Hum. Reprod., October 1, 2005; 11(10): 711 - 713. [Full Text] [PDF] |
||||
![]() |
N. Otting, C. M. C. Heijmans, R. C. Noort, N. G. de Groot, G. G. M. Doxiadis, J. J. van Rood, D. I. Watkins, and R. E. Bontrop Unparalleled complexity of the MHC class I region in rhesus macaques PNAS, February 1, 2005; 102(5): 1626 - 1631. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Daza-Vamenta, G. Glusman, L. Rowen, B. Guthrie, and D. E. Geraghty Genetic Divergence of the Rhesus Macaque Major Histocompatibility Complex Genome Res., August 1, 2004; 14(8): 1501 - 1515. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |